Dengue is one of the world’s fastest-growing mosquito-borne viral diseases, infecting an estimated 400 million people annually. Up to 100 million individuals develop symptomatic disease, and thousands die each year from severe complications. Symptoms include high fever, intense muscle and joint pain, and, in severe cases, subcutaneous bleeding, capillary leakage, shock, and organ impairment.
Mosnodenvir is a novel antiviral candidate currently in Phase 2 clinical development. By disrupting the essential NS3/NS4B protein complex, it demonstrates potent activity against all known dengue virus serotypes and variants. Its broad-spectrum efficacy positions Mosnodenvir as a promising candidate for both the treatment and prevention of dengue infection.
